THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era Thursday, March 26, 2026

COMPOUND WATCH

Wegovy HD (semaglutide 7.2mg) — FDA APPROVED, April launch confirmed STEP UP Phase 3 (1,407 adults, no T2D): 20.7% mean weight loss at 72 weeks (per-protocol) vs. 17.5% for 2.4mg. Broader treatment regimen analysis (accounting for missed doses): 18.8% vs. 15.5% — the more conservative, more clinically honest number. ~33% of HD patients lost ≥25% of body weight vs. ~17% on 2.4mg. That doubling of the responder tail is the number that matters. April launch via GoodRx, NovoCare, and traditional pharmacies. Pricing not yet announced — see WHAT TO WATCH.

Setmelanotide (Imcivree) — FDA EXPANDED INDICATION, ~March 19 [Phase 3] First approved treatment for acquired hypothalamic obesity (AHO). Phase 3 TRANSCEND trial (142 patients): 15.8% BMI reduction at 52 weeks vs. 2.6% increase on placebo — placebo-adjusted delta: 18.4%. MC4R pathway. ~10,000 US patients estimated. Not a gray-market compound — but the MC4R mechanism is exactly what biohackers are already experimenting with via melanotan analogs. This is the clinical benchmark for that pathway.

Icotrokinra (icotyde) — FDA APPROVED March 18 [Phase 3] First oral peptide to hit a biologic target (IL-23R). ~65% clear/almost-clear skin at 16 weeks; >74% by week 24. Statistically superior to Sotyktu in head-to-head. Approved adults and pediatric 12+. Proof-of-concept that oral peptide delivery is an engineering problem, not a biological impossibility.

BPC-157 [Anecdotal] — 0 human RCTs. First Phase 2 trial (hamstring strain, NCT07437547) now recruiting. Zero human data era is ending — but Phase 2 is safety and dosing, not efficacy confirmation.

GLP-1 discontinuation risk [Observational] — BMJ Medicine, March 18: 333,000+ US veterans with T2D, 3-year follow-up. Stopping GLP-1s linked to 22% rise in cardiac events. Observational, not RCT — but the sample size demands respect. Caveat: Cleveland Clinic data shows 35.2% of discontinuers received alternative obesity treatment within 1 year, so the cold-stop population is a subset. If you're on tirzepatide or semaglutide for cardiovascular reasons beyond weight, stopping is not a neutral act.

TB-500 [Animal] — UK lab test: 0 detectable compound in Amazon-listed products. See VENDOR SIGNAL.

VENDOR SIGNAL

[Flagged] — Amazon UK (BPC-157, TB-500 listings, now removed) ITV Tonight commissioned independent lab testing of Amazon-listed BPC-157 and TB-500. Result: zero detectable trace of either compound. Products were packaged to resemble standard food supplements. Amazon removed listings after ITV's findings.

This is a UK action, not US FDA enforcement. But the inference is global: if a broadcaster can commission a lab test and find nothing in retail-channel "peptides," the same fraud is almost certainly present in US supplement-channel products. This isn't an edge case — it's the base rate for unverified retail-channel peptides.

[COA Only] — Peptro.com (Premier Peptides LLC) Press release this week advertising BPC-157, TB-500, and melanotan peptides with "HPLC testing and mass spectrometry validation." COA Only means: the vendor provides their own certificate of analysis, but no independent third-party (Finnrick, Janoshik) has verified it. COA Only is not "probably fine" — it means you're trusting the seller's own paperwork. 15–20% of supplier COAs show discrepancies when independently verified. Until Finnrick or Janoshik results appear, treat as unverified for injection purposes.

No Finnrick rating changes or new Janoshik results in today's data. Check finnrick.com directly before ordering. The ITV finding is exactly why that rating exists.

If your vendor doesn't have independent HPLC confirmation, you may be injecting excipient and nothing else.

TRIAL TRACKER

NCT07437547 — BPC-157, Phase 2 | RECRUITING [Phase 2] Acute hamstring muscle strain. Started February 2026. First registered human RCT for BPC-157 in any indication. Phase 2 is safety and dosing — it doesn't validate efficacy yet. But it ends the complete evidence vacuum. If you're using BPC-157 for soft tissue repair, bookmark this trial. Results likely 18–24 months out.

ENDO-205 — Endometriosis, Phase 1 | IND CLEARED March 23 [Phase 1 Planned] EndoCyclic Therapeutics cleared FDA IND for the first-in-class non-hormonal precision peptide for endometriosis. Targets lesions specifically — no hormonal manipulation, no systemic toxicity. Preclinical: eliminated endometriosis lesions, no safety signals in GLP tox studies. NIH-backed (NICHD). 190M+ women worldwide. Phase 1 in healthy pre-menopausal women planned. Early — but it's the first peptide IND for endometriosis, and the precision-targeting platform is directly relevant to the broader peptide-as-targeted-therapy thesis.

Brenipatide (GIP/GLP-1 dual agonist) — Asthma, Phase 2 | ENROLLING [Phase 2] Weekly injectable targeting the asthma-obesity overlap. Dual GIP/GLP-1 mechanism — potential to reduce airway inflammation AND promote weight loss simultaneously. Excludes patients already on GLP-1s. If you're tracking next-gen GLP-1 variants beyond obesity, this is the novel indication to watch.

NCT07035093 — Retatrutide, Phase 3 | RECRUITING [Phase 3] Obesity + chronic low back pain. 15.3% body weight loss at 9 months in T2D patients on highest dose. This trial adds a musculoskeletal endpoint no other GLP-1 program has targeted. If positive, it expands the retatrutide label directly into the "peptides for injury recovery" space.

THE ODDS

Source: Polymarket. Volume figures indicate contract liquidity — treat contracts under $200K as directional signals, not consensus forecasts.

Inflation >3% in 2026: 98% probability — $207K volume traded (thin; directional) Treat this as a pricing assumption, not a forecast. Practical implication: compounding pharmacies that locked in API contracts in late 2025 are likely facing margin compression as input costs rise — this is an inference from the macro signal, not confirmed compounder data. Expect price drift toward the top of the $200–500/month tirzepatide/semaglutide range by Q2. If you're on auto-ship, ask your pharmacy whether pricing is locked before the next billing cycle.

Recession by end of 2026: 36% probability — $882K volume traded The threshold where gray-market sourcing behavior historically accelerates is around 40%+ — that's the level where cost-sensitivity starts overriding quality/brand preference (rule of thumb from prior market cycles; no published study). At 36%, the current split between compounders and gray-market holds. If this crosses 40% and Wegovy HD launches above $1,200/month, watch for a meaningful shift toward QSC/SRY orders. We're 4 points away from that threshold.

Fed rate cuts in 2026: 27% probability of zero cuts — $2.5M volume traded (liquid) The highest-volume macro signal in today's data. No cuts = sustained dollar strength = modest downward pressure on Chinese API import costs in dollar terms. Not a primary driver of peptide pricing, but relevant context: if the gray-market cost math is already tight, a strong dollar provides marginal relief on Chinese-sourced API.

SIGNAL VS. NOISE

SIGNAL: Wegovy HD approval (semaglutide 7.2mg, April launch) The ≥25% responder rate doubling (17% → 33%) moves outcomes into surgical bariatric territory for a meaningful patient subset. Note the per-protocol vs. regimen analysis gap: 20.7% vs. 18.8%. Both are real numbers; the regimen analysis is more conservative and more honest about real-world adherence. Pricing announcement at launch is the actual market signal — above ~$1,200/month list, compounding demand is unaffected; at parity with 2.4mg, modest pressure; below $1,000, watch 503A tirzepatide order volume.

SIGNAL: GLP-1 discontinuation linked to 22% rise in cardiac events (BMJ Medicine) 333,000+ US veterans, 3-year follow-up. Large enough to take seriously despite observational design. The decision it supports: if you're cycling off a GLP-1 for any reason other than side effects, factor cardiovascular risk into that calculus — especially if you started for CV reasons, not just weight.

SIGNAL: ITV lab test — zero BPC-157/TB-500 in Amazon products Independent broadcaster-commissioned testing finding zero active compound is the strongest retail-channel fraud confirmation in recent memory. UK jurisdiction, global implication. The research peptide community's "always verify your source" doctrine just got mainstream media validation.

SIGNAL: Icotrokinra oral peptide approval (March 18) An engineered peptide surviving the GI tract and hitting a receptor previously accessible only by injectable biologic. The "peptides must be injected" assumption is being dismantled in the clinical pipeline. Doesn't validate BPC-157 orally — but validates the engineering problem as solvable.

SIGNAL: GLP-1 in Type 1 Diabetes — Nature Medicine (174,000+ patients) GLP-1 RA initiation in T1D: 15% reduced risk of major cardiovascular events, 19% lower risk of end-stage kidney disease. No increased hospitalizations for DKA or severe hypoglycemia. Observational — randomized trials still needed. But the sample size and journal quality make this a real signal for anyone on GLP-1s for reasons beyond weight.

NOISE: RFK Jr. "within weeks" peptide unban The "within weeks" window from his late-February Joe Rogan comments has elapsed. No Federal Register notice. No named peptide officially reclassified. The Atlantic confirmed HHS did not respond to a request for comment. BPC-157, TB-500, CJC-1295, Ipamorelin, and GHK-Cu remain Category 2 operationally. Do not make sourcing decisions based on a podcast.

NOISE: MLPH peptide for hair loss (DGIST, mouse study) Mice. Biomedicine & Pharmacotherapy. "Comparable to minoxidil in mice" describes approximately 200 compounds that never worked in humans. File under: interesting preclinical, revisit if Phase 1 data appears.

REGULATORY RADAR

RFK reclassification: still no formal action. The Atlantic piece confirms Kennedy teased action on Rogan in late February. The "within weeks" window has passed. No Federal Register notice. No named peptide officially reclassified. The signal to act on is a Federal Register notice — not another podcast appearance. Until that notice appears, the Category 2 list is operationally unchanged.

Hims-Novo deal: operational by end of March. Hims was charging $99/month for compounded semaglutide before pulling it under legal pressure from Novo (patent infringement suit filed the same day Hims launched the $99 product; HHS referred Hims to DOJ). Under the new deal, Hims offers branded Ozempic injections and Wegovy (injectable and tablet) through its platform. No pricing announced for the Novo-branded Hims channel. If Novo prices the Hims channel anywhere near $1,350/month list — even with a telehealth discount — this is a 5–10x price increase for patients who were on the $99 plan. That's the number to watch when Hims announces pricing, expected by end of March. The 503A compounders who absorbed Hims overflow in February are likely to retain those patients unless Novo prices aggressively.

Novo FDA warning letter #2: Second letter in under a month over the "There's Only One Ozempic" DTC TV ad — FDA found false/misleading efficacy claims implying superiority over other GLP-1s without substantiation. Ironic timing given Lilly's competitive pressure.

Semaglutide patent expiry in China (March 20): 10+ domestic biosimilar applications filed with NMPA. Novo defensively cut Chinese prices roughly in half — "Nuohetai" (diabetes) as low as ¥329/unit; "Nuohaying" (weight loss) as low as ¥388/unit. China market story, not US compounding story — but the global price floor is moving down faster than projected.

Enforcement posture unchanged: FDA is playing whack-a-mole with gray-market vendors (The Atlantic's framing). Shutting down compounding pharmacies "would likely prompt protracted court battles." That's not a green light — it's a description of resource constraints.

WHAT TO WATCH

Now: Check Finnrick before ordering any BPC-157 or TB-500. The ITV zero-compound finding applies to any unverified retail-channel source. COA Only ≠ verified. If your vendor doesn't have independent HPLC confirmation, you don't know what you're injecting.

Now: If you're on a GLP-1 and considering cycling off, factor the BMJ discontinuation data (22% cardiac event rise) into that decision — especially if cardiovascular risk is part of your reason for being on it.

End of March: Hims pricing announcement for Novo-branded products. The $99 → new price delta is the consumer impact number. Anything above ~$300/month represents a 3x+ increase for former Hims compounded users.

April (launch week): Wegovy HD pricing. Above ~$1,200/month list = compounding demand stable. At parity with 2.4mg = modest pressure on 503A tirzepatide. Below $1,000/month = watch compounder capacity reallocation.

Q2 2026: Orforglipron FDA obesity decision. Binary event. Approval likely priced in. The pricing announcement within 24 hours of approval is the actual signal. Above ~$400/month self-pay = compounding demand intact. Below = watch for compounder capacity reallocation away from semaglutide/tirzepatide.

Ongoing: RFK reclassification. Federal Register notice = act. Podcast = noise. Do not stock up on BPC-157 in anticipation of regulatory loosening that has not formally occurred.

SCORECARD: We flagged March 20–24 as the India semaglutide patent expiry window (medium confidence, March 23 issue — prediction: multiple Indian generics would launch at significantly lower price points than brand). Confirmed and exceeded — patent expired March 20; Sun Pharma launched Noveltreat (weight management) at ₹900–₹2,000/month (~$10–24 USD) and Sematrinity (T2D) at ₹750–₹1,300/month (~$9–16 USD). Pricing more aggressive than projected. ✓ No US legal import pathway exists. Customs seizure risk remains high for any gray-market import attempt.

One number to carry into the weekend: 22%. That's the rise in cardiac events observed in GLP-1 users who stopped their medication, per 333,000+ veterans over three years. The 33% Wegovy HD responder rate gets the headlines. The 22% discontinuation risk is the number that should inform your next conversation with your prescriber about what staying on — or coming off — actually means.

Reply to this email with feedback — sourcing questions, vendor reports, or data corrections all get read.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $15/month. Manage your subscription.